BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 25940043)

  • 1. Translating the genetics of cystic fibrosis to personalized medicine.
    Corvol H; Thompson KE; Tabary O; le Rouzic P; Guillot L
    Transl Res; 2016 Feb; 168():40-49. PubMed ID: 25940043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Challenges of personalized medicine for cystic fibrosis].
    Corvol H; Taytard J; Tabary O; Le Rouzic P; Guillot L; Clement A
    Arch Pediatr; 2015 Jul; 22(7):778-86. PubMed ID: 26021452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
    Kuk K; Taylor-Cousar JL
    Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations.
    Harutyunyan M; Huang Y; Mun KS; Yang F; Arora K; Naren AP
    Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L529-L543. PubMed ID: 29351449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new era of personalized medicine for cystic fibrosis - at last!
    Quon BS; Wilcox PG
    Can Respir J; 2015; 22(5):257-60. PubMed ID: 26083544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetics of cystic fibrosis: CFTR mutation classifications toward genotype-based CF therapies.
    Fanen P; Wohlhuter-Haddad A; Hinzpeter A
    Int J Biochem Cell Biol; 2014 Jul; 52():94-102. PubMed ID: 24631642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New treatments targeting the basic defects in cystic fibrosis.
    Fajac I; Wainwright CE
    Presse Med; 2017 Jun; 46(6 Pt 2):e165-e175. PubMed ID: 28554723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of Cystic Fibrosis with CFTR Modulators].
    Tümmler B
    Pneumologie; 2016 May; 70(5):301-13. PubMed ID: 26894479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetics of Cystic Fibrosis: Clinical Implications.
    Egan ME
    Clin Chest Med; 2016 Mar; 37(1):9-16. PubMed ID: 26857764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR.
    Zhang W; Zhang X; Zhang YH; Strokes DC; Naren AP
    Drugs Today (Barc); 2016 Apr; 52(4):229-37. PubMed ID: 27252987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of CFTR modulators for the treatment of cystic fibrosis.
    Lopes-Pacheco M; Pedemonte N; Veit G
    Expert Opin Drug Discov; 2021 Aug; 16(8):897-913. PubMed ID: 33823716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurements of Functional Responses in Human Primary Lung Cells as a Basis for Personalized Therapy for Cystic Fibrosis.
    Awatade NT; Uliyakina I; Farinha CM; Clarke LA; Mendes K; Solé A; Pastor J; Ramos MM; Amaral MD
    EBioMedicine; 2015; 2(2):147-53. PubMed ID: 26137539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cystic fibrosis - an example of personalized and precision medicine.
    Skov M; Hansen CR; Pressler T
    APMIS; 2019 May; 127(5):352-360. PubMed ID: 30761610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cystic fibrosis: molecular update and clinical implications].
    Orozco L; Chávez M; Saldaña Y; Velázquez R; Carnevale A; González-del Angel A; Jiménez S
    Rev Invest Clin; 2006; 58(2):139-52. PubMed ID: 16827266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Personalized medicine in cystic fibrosis: genistein supplementation as a treatment option for patients with a rare S1045Y-CFTR mutation.
    Arora K; Yarlagadda S; Zhang W; Moon C; Bouquet E; Srinivasan S; Li C; Stokes DC; Naren AP
    Am J Physiol Lung Cell Mol Physiol; 2016 Aug; 311(2):L364-74. PubMed ID: 27261451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cystic fibrosis transmembrane conductance regulator modulators for personalized drug treatment of cystic fibrosis: progress to date.
    Becq F
    Drugs; 2010 Feb; 70(3):241-59. PubMed ID: 20166764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New and emerging targeted therapies for cystic fibrosis.
    Quon BS; Rowe SM
    BMJ; 2016 Mar; 352():i859. PubMed ID: 27030675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CFTR Folding: From Structure and Proteostasis to Cystic Fibrosis Personalized Medicine.
    McDonald EF; Meiler J; Plate L
    ACS Chem Biol; 2023 Oct; 18(10):2128-2143. PubMed ID: 37730207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
    Pettit RS
    Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CFTR dysfunction in cystic fibrosis and chronic obstructive pulmonary disease.
    Fernandez Fernandez E; De Santi C; De Rose V; Greene CM
    Expert Rev Respir Med; 2018 Jun; 12(6):483-492. PubMed ID: 29750581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.